Oncology

Your Article Summary

See Latest Articles

Ligustrazine inhibits B16F10 melanoma metastasis and suppresses angiogenesis induced by vascular endothelial growth factor
Biochemical and Biophysical Research Communications, 07/22/09

Chen L et al. - In a study to investigate anti-angiogenic properties of ligustrazine in a series of in vitro and in vivo models, data suggest that ligustrazine may inhibit tumor metastasis, at least in part, through its anti-angiogenic activity.

• Angiogenesis is crucial for tumor metastasis, with many compounds that inhibit tumor metastasis acting through suppression of angiogenesis.

• Ligustrazine inhibited VEGF-induced human umbilical vein endothelial cell (HUVEC) migration and tube formation in a dose-dependent manner in vitro, and had limited cytotoxicity to HUVECs and normal fibroblasts even at a dose up to 100 μg/ml.
• Ligustrazine suppressed VEGF-induced rat aortic ring sprouting dose-dependently.
• In vivo, ligustrazine reduced the Hb content in a matrigel plug implanted in mice and inhibited new vessel formation in CAM.
• In a B16F10 spontaneous metastasis model, ligustrazine decreased expression of CD34 and VEGF in primary tumor tissue and reduced the number of metastasis nodi on the lung surface.

Today in Dermatologic Oncology...keeping you current

Receive free subspecialty "5-minute updates" via email

Beclin 1 and LC3 autophagic gene expression in cutaneous melanocytic lesions
Human Pathology, 12/19/09

Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays
Human Pathology, 12/19/09

Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center
Leukemia and Lymphoma, 12/17/09

 See all of Dermatologic Oncology